Targeting DDX3 with a small molecule inhibitor for lung cancer therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1757-4684|7|5|648-669

ISSN： 1757-4676

Source： EMBO Molecular Medicine, Vol.7, Iss.5, 2015-05, pp. : 648-669

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Survival analysis of patients with advanced non‐small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi‐center retrospective study

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 278-283

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic variations in SLC3A2/CD98 gene as prognosis predictors in non‐small cell lung cancer

By  

Molecular Carcinogenesis, Vol. 54, Iss. S1, 2015-06 ,pp. : E52-E60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reappraisal of the role of postoperative radiation therapy in patients with pIIIa‐N2 non‐small cell lung cancer: A propensity score matching analysis

By  

Thoracic Cancer, Vol. 6, Iss. 5, 2015-09 ,pp. : 570-578

John Wiley & Sons Inc

Access to resources Recommend Favorite

Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 99-104

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current small cell lung cancer treatment in China

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 233-238

John Wiley & Sons Inc

Access to resources Recommend Favorite